David Scadden
CIK: 0001707715
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 17, 2026EDIT
Editas Medicine, Inc.
Award(A)DirectStock Option (right to buy)
51.7K shares- - Nov 12, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct200 shares at avg. $18.09$4K - Nov 12, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $43.84$9K - Oct 8, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $41.00$8K - Oct 8, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct200 shares at avg. $18.09$4K - Sep 30, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $40.00$8K - Sep 30, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct200 shares at avg. $18.09$4K - Aug 27, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $40.00$8K - Aug 27, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct200 shares at avg. $18.09$4K - Jul 10, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct1.4K shares at avg. $18.09$25K - Jul 10, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct1.4K shares at avg. $40.00$56K - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 6, 2025EDIT
Editas Medicine, Inc.
Award(A)DirectStock Option (right to buy)
37.5K shares- - Dec 11, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct200 shares at avg. $18.09$4K - Dec 11, 2024AGIO
AGIOS PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $46.28$9K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 17, 2026 |  EDIT Editas Medicine, Inc. | Award(A) Stock Option (right to buy) | 51,700 | - | - | Direct |
| Nov 12, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 200 | $18.09 | $3,618 | Direct |
| Nov 12, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 200 | $43.84 | $8,768 | Direct |
| Oct 8, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 200 | $41.00 | $8,200 | Direct |
| Oct 8, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 200 | $18.09 | $3,618 | Direct |
| Sep 30, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 200 | $40.00 | $8,000 | Direct |
| Sep 30, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 200 | $18.09 | $3,618 | Direct |
| Aug 27, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 200 | $40.00 | $8,000 | Direct |
| Aug 27, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 200 | $18.09 | $3,618 | Direct |
| Jul 10, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,400 | $18.09 | $25,326 | Direct |
| Jul 10, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 1,400 | $40.00 | $56,000 | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 6, 2025 | EDIT Editas Medicine, Inc. | Award(A) Stock Option (right to buy) | 37,500 | - | - | Direct |
| Dec 11, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 200 | $18.09 | $3,618 | Direct |
| Dec 11, 2024 | AGIO AGIOS PHARMACEUTICALS, INC. | Sale(S) | 200 | $46.28 | $9,256 | Direct |
1-20 of 20 transactions
About Scadden David
Scadden David (SEC CIK 0001707715) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO) and Director of Editas Medicine, Inc. (EDIT).
Signal8 holds 10 ownership filings by Scadden David, all Form 4s, filed between Dec 13, 2024 and Jun 23, 2026. Those filings report 20 transactions, from Dec 11, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Scadden David's filings is in CAMBRIDGE, MA.
Recent filings by Scadden David
- Jun 18, 2026: Grants or awards of AGIO derivative securities (2 lines, Form 4, code A).
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 17, 2026: Grant or award of EDIT derivative securities (Form 4, code A).
- Nov 12, 2025: Option exercise of AGIO shares (Form 4, code M).
- Nov 12, 2025: Open-market sale of AGIO shares (Form 4, code S).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Gheuens Sarah, Chief Medical Officer
- Backstrom Jay T., Director
- Ballal Rahul D., Director
- CAPELLO JEFFREY D, Director
- Foster-Cheek Kaye I, Director
- FOUSE JACQUALYN A, Director